Detalhe da pesquisa
1.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483101
2.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood
; 130(17): 1903-1910, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28819011
3.
Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment.
Haematologica
; 104(4): 789-796, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30514802
4.
Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice.
Br J Haematol
; 180(5): 666-679, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318593
5.
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
Blood
; 135(22): 2000-2004, 2020 05 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32181815
6.
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Blood
; 125(17): 2669-77, 2015 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-25736311
7.
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.
Blood
; 125(5): 856-9, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25634617
8.
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Br J Haematol
; 175(3): 410-418, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27378674
9.
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
Blood
; 124(8): 1288-95, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859361
10.
Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Blood
; 123(21): 3255-62, 2014 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24735962
11.
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Blood
; 123(19): 2953-9, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24652994
12.
PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia.
Blood
; 124(3): 420-5, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916506
13.
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Lancet Oncol
; 16(2): 169-76, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25555420
14.
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.
Blood
; 121(18): 3650-7, 2013 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-23525797
15.
Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma.
Histopathology
; 67(1): 62-9, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25431344
16.
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Br J Haematol
; 158(3): 355-62, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22640180
17.
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).
Blood
; 115(8): 1530-3, 2010 Feb 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-20032504
18.
Effect of FCGR2A and FCGR3A variants on CLL outcome.
Blood
; 116(20): 4212-22, 2010 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-20705761
19.
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
Leukemia
; 36(1): 177-188, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34244612
20.
Cyclophosphamide for CLL: to be or not CYP2B activated?
Blood
; 122(26): 4156-7, 2013 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-24357708